{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-24-000114","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.371688+00:00","generated_at":"2026-05-31T11:05:16.067474+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rallybio Q2 net loss $16.2M; cash $88.6M; RLYB212 Phase 2 on track for Q4 2024","bullets":["Q2 net loss $16.2M ($0.37/share) vs $18.6M ($0.46/share) in Q2 2023.","Revenue $0.3M from J&J collaboration; no revenue in prior year.","Cash, equivalents, and securities $88.6M as of June 30, expecting runway into mid-2026.","RLYB212 Phase 2 trial in pregnant women at risk of FNAIT remains on track to start Q4 2024.","Epidemiological analysis estimates >30,000 higher-risk pregnancies/year in North America and major European countries, 40% above prior estimates."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-24-000114","json":"https://secwatch.observer/filing/0001739410-24-000114.json","markdown":"https://secwatch.observer/filing/0001739410-24-000114.md","text":"https://secwatch.observer/filing/0001739410-24-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000114/0001739410-24-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000114/rlyb-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:05:16.067474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}